Recombinant adeno-associated virus serotype 2 (rAAV2) vectors have shown promise as therapeutic agents for neurologic disorders. However, intracerebral administration of this vector leads to preferential transduction of neurons and a restricted region of transgene expression. The recently developed rAAV vectors based upon nonserotype 2 viruses have the potential to overcome these limitations. Therefore, we directly compared a rAAV type 1 to a type 2 vector in the murine brain. The vectors were engineered to carry identical genomes (AAV2 terminal repeat elements flanking an enhanced green fluorescent protein expression cassette) and were administered by stereotaxic-guided intracerebral injection. We found that the rAAV1 vector (rAAV1-GFP) had a 13-to 35-fold greater transduction efficiency than that of the rAAV2 vector (rAAV2-GFP). Also, rAAV1-transduced cells were observed at a greater distance from the injection site than rAAV2-transduced cells. Neurons were the predominant cell type transduced by both vector types. However, in contrast to rAAV2-GFP, rAAV1-GFP was capable of transducing glial and ependymal cells. Thus, rAAV1-based vectors have biologic properties within the brain distinct from that of rAAV2. These differences might be capitalized upon to develop novel gene transfer strategies for neurologic disorders.
Introduction
Gene transfer to the central nervous system using vectors based upon adeno-associated virus type 2 (AAV2) has shown potential as a treatment for neurologic disorders. Within the brain, recombinant (r)AAV2 vectors are capable of mediating high-level, long-term expression of reporter [1] [2] [3] [4] and therapeutic transgenes. 1, [5] [6] [7] [8] [9] Importantly, adverse effects of CNS-directed, rAAV2-mediated gene transfer have not been observed. However, as a therapeutic agent in many neurologic disorders, this vector is limited by a small region of transduction following intracerebral administration 9, 10 and inefficient transduction of glial and ependymal cells. 1, 2, 11, 12 Coadministration of this vector with heparin [13] [14] [15] or mannitol 10 alone or in combination with convection-enhanced delivery techniques 13, 14 has been shown to increase the region of transduction. Also, it might be possible to redirect rAAV2 tropism to non-neuronal cells through genetic modification of the capsid [16] [17] [18] and the use of bispecific antibodies. 19 However, the usefulness of these techniques is reduced by potential toxicity, modest increases in the region of transduction, and relatively low transduction efficiency.
Recently, gene transfer vectors based upon other AAV serotypes (1 and 3-8) have been developed. [20] [21] [22] [23] [24] [25] In vivo investigations have shown that these vectors differ in their ability to transduce specific cell types and organs (ie different tropism). [24] [25] [26] [27] [28] The vectors have two general designs: (i) capsid and terminal repeat (TR) elements originating from the same virus serotype and (ii) hybrid vectors consisting of AAV2 TR elements packaged in non-AAV2 serotype capsids. The hybrid vector design capitalizes upon the ability of AAV2 TR elements to mediate long-term in vivo expression and provides a means to directly compare different capsids without the confounding variable of different cis-acting sequences.
Within the brain, a limited number of studies have been performed with serotypes other than rAAV2. Davidson et al 27 found significant differences among rAAV2, -4, and -5 following intrastriatal injections. rAAV2 and -5 mediated transduction of neurons, while rAAV5 also transduced astrocytes and ependymal cells; rAAV4 transduced only ependymal cells. In addition to the expanded tropism, rAAV5 mediated a more widely dispersed pattern of transduction. Mastakov et al, 15 also reported that rAAV5, as compared to rAAV2, mediated more widespread transgene gene expression within the CNS following direct intracerebral injection. The results of these studies suggest that intraparenchymal diffusion and the ability to transduce non-neuronal cells are a function of the different binding specificities of each vector. 24, [29] [30] [31] Considering that rAAV1 has a different affinity for cell surface moieties than AAV types 2-5 24 and transduces neuronal cells within the retina 28 , we hypothesized that this vector would mediate gene transfer to the brain and have biologic properties within this organ different from the previously studied vectors.
Results and discussion
To explore the use of rAAV1 vectors within the CNS, we performed a series of experiments directly comparing the transduction efficiency and tropism of a hybrid rAAV1 24 with a rAAV2 vector. Two rAAV vectors (designated as rAAV1-GFP and rAAV2-GFP) were engineered to carry identical genomes consisting of the AAV type 2 TR elements flanking a cytomegalovirus immediate-early (CMV-IE) promoter-driven enhanced green fluorescent protein (EGFP) transgene. This transgene was chosen because the CMV-IE promoter in the context of rAAV2 TR elements directs high-level transgene expression for at least 60 days within the murine CNS 3,4,9 and EGFP can be readily assayed for by several different methods. Moreover, since EGFP remains intracellular, its presence directly coincides with transduced (transgene-positive) cells. To compare the transduction efficiency and tropism of different vectors, a single titration method that can accurately quantify each vector should be used. Since the genomes of the rAAV2-GFP and rAAV1-GFP vectors are identical, we used a PCR-based titration method to determine the number of encapsidated vector genomes (DNase-resistant particle (DRP) titer). 32 The titers of the vector preparations were 2.1 Â 10 13 DRP/ml for rAAV2-GFP and 2.6 Â 10 11 for rAAV1-GFP. The concentration of vector particles (DRPs) in the rAAV2-GFP preparation was adjusted to equal that of the rAAV1-GFP preparation. Postdilution analysis confirmed that an identical number of encapsidated viral genomes (DRPs) were used in the following experiments.
The rAAV vectors were injected into the striatum of adult C3H/HeJ mice via stereotaxic-guided intracerebral injections. Groups of mice were killed at 2 and 5 weeks postvector administration. The brains were serially sectioned and evaluated by fluorescent microscopy. At 2 weeks postinjection, EGFP expression was present only in the animals receiving the rAAV1-GFP vector. However, by 5 weeks postinjection, rAAV2-and rAAV1-GFPtransduced cells were observed ( Figure 1 ). The timedependent increase in the number of rAAV2-transduced cells within the CNS has been described. 3, 4 All subsequent analyses were performed at the 5-week time point.
For both vectors, the highest level of EGFP fluorescence was near the injection site (Figure 1a and b) . Within the striatum, EGFP expression extended 0.9270.07 mm in the rostral-caudal direction in the rAAV2-injected mice and 2.8270.28 mm in the rAAV1-injected mice. In the rAAV2-injected mice, EGFP-positive cells were observed primarily near the site of injection. This restricted region of expression mediated by rAAV2 vectors is believed to result from rapid heparan-sulfate proteoglycan-dependent uptake of rAAV2 particles by neurons 12 or binding of the vector to these moieties within the extracellular matrix. In the rAAV1-injected mice, transduced cells were more widespread. EGFP expression was present within a contiguous region involving the striatum, corpus callosum, external capsule, and periventricular area (Figure 1b) . Also, EGFP was observed at more distant sites (Figure 1c-f ). At these distant sites, we evaluated whether EGFP expression was within cell bodies (indicating transduction of cells within that location) or cellular processes (suggestive of anterograde transportation of EGFP within axons originating from a transduced neuron with the cell body at a different location). EGFP-positive cell bodies (and cellular processes) were present within diverse structures including the olfactory bulb, piriform cortex, neocortex, and hippocampus. EGFP-positive cellular processes (without cell bodies) were present in the globus pallidus, substantia nigra, and brainstem. This observed pattern of EGFP expression might result from several mechanisms. The contiguous region of transgene expression is likely the result of intraparenchymal diffusion of the vector as described for rAAV5. 15, 27 EGFP-positive fibers within the substantia nigra and globus pallidus are the predicted result of anterograde transportation of the transgene product along striatal projections (ie efferent axonal projections from transduced neurons within the striatum to these structures). However, these mechanisms (diffusion of the vector or anterograde transportation of EGFP) do not offer a full explanation for the EGFP-positive cell bodies within the hippocampus and olfactory bulb. Both structures are at a significant distance from the site of injection making simple diffusion of the vector unlikely. Moreover, we did not observe a decreasing gradient of transduction, as would be expected with intraparenchymal diffusion, from the site of injection to the hippocampus or olfactory bulb. Since efferent and afferent neuronal projections exist between the hippocampus and lateral septal nuclei, we can speculate that rAAV1 reached the hippocampus via retrograde transportation. Thus, following intraparenchymal diffusion of the vector to the ipsilateral lateral septal area (Figure 1b) , the vector entered efferent fibers and was transported to the hippocampus. In contrast, only GFP-positive fibers and not cell bodies are found within the hippocampus following injection of an rAAV2 vector into the septal area. 33 As for the olfactory bulb, the transduced cells have features characteristic of interneurons within the granular layer of this structure. These cells do not have axonal projections out of the olfactory bulb. Recently, Passini et al 34 observed transgene-mediated expression of the lysosomal enzyme b-glucuronidase within this olfactory bulb cell population following intrastriatal rAAV2 administration. The authors did not find transgene-derived mRNA within these cells. They concluded that the b-glucuronidase-positive interneurons originated from the neural progenitor cell population within the subventricular zone (SVZ) of the lateral ventricle and that these cells acquired secreted b-glucuronidase during migration to the olfactory bulb (see Alvarez-Buylla et al 35 for a review of SVZ progenitor cell differentiation and migration to the olfactory bulb). However, unlike bglucuronidase, EGFP is neither secreted nor taken up by cells. Therefore, it is possible that AAV1-based vectors are capable of transducing SVZ neural progenitor cells (note the high level of transduction within the SVZ of the lateral ventricle in Figure 1b ) or migrating cells en route to the olfactory bulb. These observations are speculative and require further exploration.
To quantify transgene expression, we measured EGFP levels in the brains of mice 5 weeks postinjection using an EGFP ELISA (Figure 2a) . Consistent with the fluorescent microscopic data, the highest levels of expression were in the region encompassing the injection site (rostral 1/3 of the injected hemisphere, region A). In the rAAV1-injected mice, the level of transgene-derived protein was 35-fold higher than that in the rAAV2-rAAV type 1 gene transfer to the murine brain C Wang et al injected mice (Po0.00005), accounting for approximately 0.1% of the total protein within this region. In the caudal 2/3 of the hemisphere (region B), EGFP levels mediated by rAAV1-GFP were approximately 25% of that near the injection site and close to background levels in the rAAV2-injected mice. EGFP was not detected in the hemisphere contralateral to the injection site in any of the animals. To correlate transgene expression with the presence of vector genomes, we performed a real-time quantitative PCR assay designed to detect the CMV-IE promoter. Consistent with the expression data, 13-fold more vector genomes were present in the rAAV1-injected than in the rAAV2-injected animals (region A, Po0.00005; Figure 2b ). The data presented in Figure 2 suggest that rAAV1 has a wider distribution of transduction than rAAV2. Specifically, the differences between regions A and B for rAAV1 are less than those for rAAV2. To test this statistically, we examined the interaction between vector type and location (regions A and B; ANOVA with repeated measures) and found a significant interaction between these variables for both vector genome (P¼0.0001) and EGFP (P¼0.02) levels. Thus, the quantitative assays support our microscopic observations that rAAV1 mediated transduction further away from the injection site than rAAV2. Figure 1 Comparison of rAAV2-GFP and rAAV1-GFP transduction within the murine CNS. The genomes of the rAAV vectors consisted of (i) the AAV type 2 terminal repeat elements at the 5 0 and 3 0 ends of the genome, (ii) the cytomegalovirus immediate-early (CMV-IE) promoter/enhancer and a 5 0 -untranslated region containing a simian virus 40 (SV40) intron subcloned from pCMVb (BD Biosciences Clontech, Palo Alto, CA, USA), (iii) the EGFP coding region subcloned from pEGFP-N1 (BD Biosciences Clontech), and (iv) an SV40 polyadenylation signal. The vectors were produced from HeLaderived stable producer cell lines containing integrated copies of the above genetic elements and AAV rep and cap. 37 For the AAV type 2 vector, the Rep and Cap genes were originally derived from pSub201. 38 The AAV genes for the type 1 hybrid vector were derived from pXR1. 24 The AAV2 vector (rAAV2-GFP) was affinity-column purified with a heparin sulfate resin (HE20 POROS, Applied Biosystems, Foster City, CA, USA). 32 The AAV1 hybrid vector (rAAV1-GFP) was purified over an iodixanol density gradient 39 followed by anionic column chromatography (HQ POROS, Applied Biosystems). rAAV particle titers were determined using a quantitative PCR assay to measure the number of DNase-resistant vector genomes.
32 C3H/HeJ mice (The Jackson Laboratory, Bar Harbor, ME, USA) at 7-8 weeks of age underwent stereotaxic-guided intracranial injections as previously described. 9 Each animal was injected with 5.2 Â 10 8 DRP (2 ml total volume) into the right striatum according to published coordinates. 40 The 0 -tetramethylbenzidine (T8665 substrate system; Sigma-Aldrich, Co., St. Louis, MO, USA) was added and the product read at 450 nm absorbance. The amount of EGFP was determined by comparison with known quantities of purified EGFP (BD Biosciences Clontech) diluted in protein homogenates of control mouse brain. The mean EGFP levels (pg/mg total cellular protein) are shown for mice injected with rAAV2-GFP (n¼3) and rAAV1-GFP (n¼3). (b) To evaluate for the presence of rAAV sequences within the brain, total genomic DNA was isolated using a column purification procedure (DNeasy Tissue Kit, Qiagen, Valencia, CA, USA). Vector genomes were measured by a fluorescence-based, real-time, quantitative PCR assay (ABI PRISM 7700 Sequence Detection System; Perkin-Elmer, Foster City, CA, USA) using primers and probe designed to anneal to the CMV-IE promoter region of the vector genome. 32 The mean numbers of vector genomes for the rAAV2-injected (n¼3) and rAAV1-injected mice are shown (n¼3). Error bars represent standard deviation of the mean. The data were analyzed by analysis of variance with vector type as the factor variable. The Bonferroni test was applied to pairwise comparisons. Po0.05 was considered statistically significant. Asterisks indicate degree of statistical significance of comparisons between the same regions (A or B) of mice injected with rAAV2 and rAAV1. *Po0.01; **Po0.00005; ***Po0.000005. Figure 3 Evaluation of transgene-mediated EGFP expression by fluorescent activated-cytometry within the CNS 5 weeks after vector injection. Mice received bilateral intrastriatal injections of the vectors. The brains from rAAV2-GFP-injected, rAAV1-GFP-injected, and uninjected mice were removed from the calvarium, stripped of the meninges, and dissected as indicated in Figure 2 . The tissue samples were digested with trypsin (0.25%) and DNAse I (1 mg/ml) at 371C for 30 min. Following digestion, cells were dissociated by trituration, collected by centrifugation, resuspended in a phosphate-buffered saline, filtered through a 70 mm cell strainer (Becton Dickinson, Franklin Lakes, NJ, USA), and fixed in 4% paraformaldehyde (41C for 10 min). After fixation the cells were placed in ice-cold PBS at 1 Â 10 6 cells/ml and analyzed for the presence of EGFP by flow cytometry. The cytometer parameters were set such that less than 0.5% of control cells would be positive. Representative results for control and vector injected mice are shown. The y-axis is the forward angle light scatter (FALS; a measure of cell size) and the x-axis is the fluorescent intensity (a measure of EGFP expression). The region positive for EGFP is labeled as r1 in the control sample. 
To measure the number of transduced cells, we performed flow cytometry on neural cells isolated from the CNS of mice following rAAV vector injection. All mice in this analysis received bilateral injections. The hemispheres were analyzed separately (n¼4 for each vector; Figure 3 ). rAAV1-GFP transduced 15.973.2% of cells in the rostral 1/3 (region A) and 2.971.9% of cells in the caudal 2/3 (region B) of the injected hemisphere compared to 1.170.2 and 0.270.2% for rAAV2-GFP (region A: P¼0.000005; region B: Po0.05). Thus, the data obtained from the four complementary assays (fluorescent microscopy, ELISA, PCR, and flow cytometry) were consistent in demonstrating that rAAV1 hybrid vectors have a transduction efficiency exceeding that of rAAV2.
Our initial microscopic evaluation suggested that rAAV1-GFP transduced a broader range of cell types than rAAV2-GFP (eg cells within the corpus callosum, external capsule, and periventricular region; compare Figure 1a and b) . To examine the tropism of rAAV1-GFP, we performed a detailed microscopic analysis. Confocal immunofluorescent microscopy was performed to colocalize EGFP expression to different neural cell types (Figure 4a -f) using antibodies directed against cell-typespecific epitopes for neurons (NeuN), astrocytes (GFAP), oligodendrocytes (CNPase), and microglia (F4/80). In the rAAV2-injected mice, the majority of EGFP-positive cells were immunoreactive with NeuN consistent with past observations that rAAV2 vectors predominantly transduce neurons. 1, 2, 11, 12 In addition, near the injection track, rare GFAP-positive cells (astrocytes) were transduced. Others have suggested that transduction of astrocytes by rAAV2 is the result of phagocytosis by reactive astrocytes and not a receptor-mediated event. 12 Alternatively, rAAV2 transduction of astrocytes might require a multiplicity of infection that could only be reached at the site of vector administration or the use of glial-specific promoters. 36 Our finding of rAAV2-transduced astrocytes near the needle track (a site of astrocyte activation and high multiplicity of infection) does not differentiate between these possibilities. In the rAAV1-injected mice, a different pattern of transduction was observed. Although neurons continued to be the predominant cell-type transduced (Figure 4b ), substantial numbers of EGFP-positive glial cells were identified. EGFP was found within astrocytes ( Figure 4d ) not only near the injection site but also several millimeters away within the striatum, corpus callosum, and external capsule. The high level of EGFP expression within white matter tracts that did not colocalize with GFAP suggested that other glial cell types (eg oligodendrocytes) were transduced. Indeed, we identified transgene expression within oligodendrocytes (Figure 4e ) and microglia (Figure 4f ) in the corpus callosum, external capsule, and striatum. To determine whether rAAV1 transduced ependymal cells, we evaluated propidium iodide-counterstained sections. EGFP expression within cuboidal cells lining the lateral ventricle ( Figure 4c ) consistent with ependymal cell transduction was observed. The ependyma appears to have been transduced via the basolateral surface, similar to what has been reported for rAAV5 vectors. 27 Quantitative comparison of the transduction efficiency of the two vectors for non-neuronal cell types was determined by counting the number of EGFP-positive glial and ependymal cells in sections spanning the region Figure 4 Localization of EGFP expression to specific neural cell types. Immunofluorescent histologic assays were performed on perfusion-fixed cryostat sections from mice killed 5 weeks after injection with rAAV2-and rAAV1-GFP vectors (n¼3 for each vector). Antibodies directed against neuron-specific nuclear protein (NeuN; mouse anti-mouse IgG, 1:200; Chemicon International, Inc., Temecula, CA, USA), glial fibrillary acidic protein (GFAP; rabbit anti-cow, 1:200; DAKO Corp., Carpinteria, CA, USA), 2 0 , 3 0 -cyclic nucleotide 3 0 -phosphodiesterase (CNPase; mouse antihuman IgG; 1:100; Chemicon International, Inc.), and 160 kDa monocyte/ macrophage surface glycoprotein (F4/80; rat anti-mouse IgG, 1:100; Serotec Inc., Raleigh, NC, USA) in conjunction with appropriate speciesspecific Alexa 594-labeled secondary antibodies (Molecular Probes, Inc., Eugene, OR, USA) were used. Ependymal cells were identified by their location (ie lining the ventricular space) in sections counterstained with propidium iodide (PI; Sigma-Aldrich, Corp.). Transduction efficiency of non-neuronal cell types was determined by counting the number of cells coexpressing EGFP and the cell-type-specific epitope (glial cells) or expressing EGFP and lining the ventricular space (ependymal cells) in the entire section. For each cell type, every fifth section spanning the region of EGFP expression was analyzed. The total number of cells per mouse was determined. The sections were visualized at Â 200 and Â 400 magnification using epifluorescent illumination (Zeiss Axioskop) with appropriate filters to visualize EGFP and Alexa 594 (alone and in combination). Only cells with clearly delineated shape were included in the analysis. Confocal laser microscopy (Zeiss LSM 410) was performed with Â 10, Â 40, and Â 100 objectives. z-Series images were captured and analyzed for cellular colocalization of EGFP and cell-type specific epitopes. Panels are representative confocal images. EGFP expression was located primarily within neurons (NeuN-positive cells) in rAAV2-(a) and rAAV1-GFP-(b) injected mice. rAAV1-mediated GFP expression was present in ependymal cells (c), astrocytes (d), oligodendrocytes (e), and microglia (f). Panels a, b, d, e, and f consist of single-color and two-color-merged images of a single z-series slice. Panel c consists of two-color-merged images. The region within the box is shown at higher magnification. Arrows indicate cells expressing EGFP and the cell-type-specific epitope. cc, corpus callosum; st, striatum; v, ventricle. Scale bars: a, b, f¼25 mm; c¼250 mm; c (inset), d, e¼10 mm. The number of transduced astrocytes in the rAAV1-GFPinjected mice was greater than that observed in the rAAV2-GFP-injected mice (7517122 vs 372; Student's ttest, Po0.0005). No other rAA2-transduced non-neuronal cell type was identified. rAAV1-mediated EGFP expression was present in 164724 oligodendrocytes, 101735 microglia, and 10457142 ependymal cells. These data indicate that rAAV1 tropism within the murine brain is distinct from that of rAAV2. We cannot use these data to define an hierarchy of rAAV1 tropism for different neural cells. This determination will require the use of promoters known to be active in each cell-type, since transcriptional activity of the CMV-IE promoter might be cell type dependent.
In conclusion, rAAV1 hybrid vectors mediate widespread gene transfer and have a higher transduction efficiency than rAAV2 vectors within the CNS following direct intraparenchymal injection. These differences make rAAV1 a potential therapeutic agent in the treatment of disorders globally affecting the CNS. In addition to improved gene transfer, rAAV1-based vectors are capable of transducing and, perhaps, selectively targeting specific glial cell-types (through cell-type specific promoters). This ability might prove useful in many gene therapy applications.
